Core Viewpoint - COSCIENS Biopharma Inc. has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited for the commercialization of Macrilen in specific Asian markets, aiming to address the unmet need for growth hormone deficiency diagnostics [1][2][3]. Company Overview - COSCIENS Biopharma Inc. focuses on pharmaceutical therapies, diagnostic products, and natural ingredient solutions, with a diverse portfolio that includes the development of natural, plant-based active ingredients [5]. - The company's lead product, Macrilen (macimorelin), is the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD) [6]. Distribution Agreement Details - The agreement with Wuzhou covers the registration, importation, and commercialization of Macrilen in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan [2]. - The partnership is structured for an initial ten-year term, with Wuzhou committing to a minimum initial order of approximately €800,000 [2]. Strategic Importance - The collaboration is expected to leverage the "Hong Kong and Macao Medicine and Equipment Connect" policy, facilitating expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area [2]. - The agreement is seen as a key step in COSCIENS' strategy to unlock the global potential of Macrilen and establish sustainable revenue streams [3]. Market Potential - The partnership aims to meet the significant demand for a convenient, oral diagnostic option for patients suspected of AGHD in the dynamic Asian markets [3]. - Wuzhou's expertise in regulatory processes and hospital networks is expected to enhance the approval pathways for Macrilen in the targeted regions [4].

Core Points - COSCIENS Biopharma Inc. has appointed Peter H. Puccetti as Interim Chief Executive Officer, succeeding Anna Biehn [1][2] - The leadership transition is part of the company's efforts to reduce costs and streamline its organizational structure while aligning resources with strategic priorities [2] - Puccetti aims to strengthen operational performance and drive shareholder value in his new role [2] Company Overview - COSCIENS is a life science company focused on natural ingredients and pharmaceutical solutions, with a diverse portfolio [3] - The company develops natural, plant-based active ingredients and commercializes pharmaceutical and diagnostic products [3] - COSCIENS' lead pharmaceutical product, Macimorelin, is the first FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3] Stock Information - COSCIENS' common shares are listed on the Toronto Stock Exchange under the symbol "CSCI" and have a trading symbol "CSCIF" for the OTC market in the United States [4]

Core Insights - COSCIENS Biopharma Inc. has voluntarily delisted from Nasdaq while retaining its listing on the TSX, marking a strategic shift to reduce public reporting obligations in the U.S. [4][5] - The company has successfully implemented a zero-based budgeting initiative, resulting in a 59% reduction in operating expenses compared to Q3 2024, leading to significantly lower cash outflows [3][15] - The gross margins improved by 700 basis points in Q3 2025 due to cost-cutting measures and operational improvements [2][3] Financial Performance - For Q3 2025, COSCIENS reported a consolidated net loss of $1.8 million, a decrease from a net loss of $5.8 million in Q3 2024, reflecting a $4.0 million improvement [15][18] - Total revenue for Q3 2025 was $1.5 million, down from $1.9 million in the same period in 2024, primarily due to decreased sales in key product lines [16][19] - Operating expenses for Q3 2025 were $2.9 million, significantly lower than $7.3 million in Q3 2024, driven by reductions in research and development costs and other expenses [17][20] Strategic Developments - The company has suspended its Juvente cosmeceuticals line due to limited success in e-commerce channels, focusing instead on core business areas [8] - COSCIENS is evaluating its pharmaceutical products, including Macrilen, which did not meet primary endpoints in a recent trial but still provides insights for future development [12] - The company is exploring new market opportunities for its active ingredients and has completed construction of its PGX technology units in Edmonton and Austria [10][11] Corporate Actions - Following the Nasdaq delisting, COSCIENS has applied for quotation on the OTCQB Venture Market, although approval is not guaranteed [4] - The company plans to file a Form 15-F with the SEC to terminate its U.S. reporting obligations, which would take effect 90 days after filing [4][5] - Management is focused on enhancing operational efficiency and reducing costs to maintain competitiveness in the current economic environment [5]

Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].